Results and insights from a phase I clinical trial of Lomecel‐B for Alzheimer's disease

HYPOTHESIS: We hypothesized that Lomecel‐B, an allogeneic medicinal signaling cell (MSC) therapeutic candidate for Alzheimer's disease (AD), is safe and potentially disease‐modifying via pleiotropic mechanisms of action. KEY PREDICTIONS: We prospectively tested the predictions that Lomecel‐B ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Brody, Mark, Agronin, Marc, Herskowitz, Brad J., Bookheimer, Susan Y., Small, Gary W., Hitchinson, Benjamin, Ramdas, Kevin, Wishard, Tyler, McInerney, Katalina Fernández, Vellas, Bruno, Sierra, Felipe, Jiang, Zhijie, Mcclain‐Moss, Lisa, Perez, Carmen, Fuquay, Ana, Rodriguez, Savannah, Hare, Joshua M., Oliva, Anthony A., Baumel, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Featured Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084163/
https://www.ncbi.nlm.nih.gov/pubmed/35357079
http://dx.doi.org/10.1002/alz.12651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084163/
https://www.ncbi.nlm.nih.gov/pubmed/35357079
http://dx.doi.org/10.1002/alz.12651

Ejemplares similares